{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:43:58Z","timestamp":1793187838470,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.modpat.2026.101093","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:41:15Z","timestamp":1791243675000},"page":"101093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Complementary Role for Immunohistochemistry and Next-Generation Sequencing (NGS) for Detection of Methylthioadenosine Phosphorylase (MTAP) Loss in Patients With Non\u2013Small Cell Lung Cancer (NSCLC)"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-1292","authenticated-orcid":false,"given":"Sanna","family":"Laaksonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Odintsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.modpat.2026.101093_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4161\/cbt.11.7.14948","article-title":"Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies","volume":"11","author":"Bertino","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105492","article-title":"Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition","volume":"300","author":"Bedard","year":"2024","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70012","article-title":"Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer","volume":"11","author":"Gorbokon","year":"2025","journal-title":"J Pathol Clin Res"},{"issue":"6278","key":"10.1016\/j.modpat.2026.101093_bib4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.modpat.2026.101093_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104535","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"10","author":"Ikushima","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.modpat.2026.101093_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/his.14324","article-title":"Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma","volume":"78","author":"Chapel","year":"2021","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","volume":"12","author":"Ashok Kumar","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.modpat.2026.101093_bib9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/cancers17071205","article-title":"Deficiency of MTAP is frequent and mostly homogeneous in pancreatic ductal adenocarcinomas","volume":"17","author":"Gorbokon","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12967-022-03823-8","article-title":"MTAP loss: a possible therapeutic approach for glioblastoma","volume":"20","author":"Patro","year":"2022","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.euo.2021.10.006","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.modpat.2026.101093_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107963","article-title":"MTAP as an emerging biomarker in thoracic malignancies","volume":"197","author":"Brune","year":"2024","journal-title":"Lung Cancer"},{"issue":"20","key":"10.1016\/j.modpat.2026.101093_bib13","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1038\/sj.onc.1202205","article-title":"Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC)","volume":"17","author":"Schmid","year":"1998","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.gendis.2022.04.001","article-title":"Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue","volume":"10","author":"Prabhu","year":"2023","journal-title":"Genes Dis"},{"issue":"11","key":"10.1016\/j.modpat.2026.101093_bib15","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/2159-8290.CD-23-0951","article-title":"Early clinical success of MTA-cooperative PRMT5 inhibitors for the treatment of CDKN2A\/MTAP-deleted cancers","volume":"13","author":"Mulvaney","year":"2023","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.modpat.2026.101093_bib16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.modpat.2026.101093_bib17","article-title":"BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007","volume":"43","author":"Arbour","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101093_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of Immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101093_bib19","first-page":"18","article-title":"OncDRS: an integrative clinical and genomic data platform for enabling translational research and precision medicine","volume":"6","author":"Orechia","year":"2015","journal-title":"Appl Transl Genom"},{"issue":"3","key":"10.1016\/j.modpat.2026.101093_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jcp-2023-209341","article-title":"Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers","volume":"78","author":"Mauri","year":"2025","journal-title":"J Clin Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/cancers17020252","article-title":"Analysis of TERT mRNA levels and clinicopathological features in patients with peritoneal mesothelioma","volume":"17","author":"d'Amati","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2026.101093_bib23","series-title":"Next-generation Sequencing in Cancer Research","author":"Wu","year":"2013"},{"issue":"10","key":"10.1016\/j.modpat.2026.101093_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jmoldx.2025.06.005","article-title":"Clinical implementation of matched tumor\/germline sequencing improves accuracy of tumor genomic profiling and therapeutic recommendations","volume":"27","author":"Manning","year":"2025","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1016\/j.modpat.2026.101093_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.11.010","article-title":"Clinical significance of MTAP deletions and their overlap with concurrent oncogenic driver alterations including EGFR in NSCLC","volume":"21","author":"Ross","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2025.08.014","article-title":"MTAP expression by immunohistochemistry: a novel biomarker in NSCLC","volume":"21","author":"Brune","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101093_bib27","first-page":"375","article-title":"Lung cancer in non-smokers","volume":"117","author":"Dubin","year":"2020","journal-title":"Mo Med"},{"issue":"5","key":"10.1016\/j.modpat.2026.101093_bib28","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1183\/09031936.00046915","article-title":"Lung cancer in never-smokers","volume":"45","author":"Planchard","year":"2015","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.modpat.2026.101093_bib29","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41379-019-0309-6","article-title":"Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma","volume":"33","author":"Kinoshita","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101093_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2019.02.004","article-title":"Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia","volume":"130","author":"Yoshimura","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.modpat.2026.101093_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101093_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.annonc.2026.03.001","article-title":"MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies","volume":"37","author":"Aldea","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.101093_bib35","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1038\/s41467-023-41670-3","article-title":"Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients","volume":"14","author":"Fontana","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41467-017-02584-z","article-title":"Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing","volume":"9","author":"Nahar","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2008.04.019","article-title":"Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma","volume":"63","author":"Watanabe","year":"2009","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.modpat.2026.101093_bib38","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ejso.2014.04.017","article-title":"MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients","volume":"40","author":"Su","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-020-57812-2","article-title":"MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab","volume":"10","author":"Jing","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.modpat.2026.101093_bib40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jnen\/nlaf033","article-title":"MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: a meta-analysis and literature review","volume":"84","author":"Dono","year":"2025","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101093_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/carcin\/bgi201","article-title":"Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma","volume":"27","author":"Hellerbrand","year":"2006","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.modpat.2026.101093_bib42","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0002-9440(10)63695-4","article-title":"Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma","volume":"163","author":"Behrmann","year":"2003","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101093_bib43","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/jcm14082622","article-title":"Epigenetic modifications as novel biomarkers for diagnosis, prognosis, and therapeutic targeting in thyroid, pancreas, and lung neuroendocrine tumors","volume":"14","author":"Colapietra","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.modpat.2026.101093_bib44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid biopsy: general concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol"},{"issue":"suppl","key":"10.1016\/j.modpat.2026.101093_bib45","article-title":"Liquid biopsy detection of gene Copy Number (CN) losses, including existing and emerging clinical targets","volume":"5","author":"Rolfo","year":"2024","journal-title":"J Liq Biopsy"},{"issue":"suppl 16","key":"10.1016\/j.modpat.2026.101093_bib46","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1200\/JCO.2024.42.16_suppl.8599","article-title":"Genomic landscape of deletions and association with alterations in NSCLC","volume":"42","author":"Thummalapalli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101093_bib47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for pathologists: protocols, pitfalls, and tips","volume":"50","author":"Kim","year":"2016","journal-title":"J Pathol Transl Med"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:31:35Z","timestamp":1793187095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0893395226001365"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101093","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Complementary Role for Immunohistochemistry and Next-Generation Sequencing (NGS) for Detection of Methylthioadenosine Phosphorylase (MTAP) Loss in Patients With Non\u2013Small Cell Lung Cancer (NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101093"}}